SEARCH

SEARCH BY CITATION

References

  • 1
    Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:158693.
  • 2
    Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50:140011.
  • 3
    Maini RN, Breedveld FC, Kalden JR et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50:105165.
  • 4
    Klareskog L, Van Der Heijde, D, De Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363:67581.
  • 5
    Smolen JS, Han C, Bala M et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005; 52:102030.
  • 6
    Den Broeder A, Van De Putte L, Rau R et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002; 29:228898.
  • 7
    Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003; 30:231518.
  • 8
    Haraoui B, Keystone EC, Thorne JC et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004; 31:23569.
  • 9
    Lequerre T, Jouen F, Brazier M et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxf) 2007; 46:44653.
  • 10
    Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:31524.
  • 11
    Dupuy AM, Badiou S, Descomps B, Cristol JP. Immunoturbidimetric determination of C-reactive protein (CRP) and high-sensitivity CRP on heparin plasma. Comparison with serum determination. Clin Chem Lab Med 2003; 41:9489.
  • 12
    Benjamini Y, Hochberg Y. Controlling the false discovery rate – a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57:289300.
  • 13
    Charles P, Elliott MJ, Davis D et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163:15218.
  • 14
    Macias I, Garcia-Perez S, Ruiz-Tudela M, Medina F, Chozas N, Giron-Gonzalez JA Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor – a blockade in patients with rheumatoid arthritis. J Rheumatol 2005; 32:21028.
  • 15
    Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position–857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxf) 2005; 44:54752.
  • 16
    De Vries N, Tak PP. The response to anti-TNF-α treatment: gene regulation at the bedside. Rheumatology (Oxf) 2005; 44:7057.
  • 17
    Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2006; 27:15761.
  • 18
    Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003; 48:184952.
  • 19
    Seitz M, Wirthmuller U, Moller B, Villiger PM. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxf) 2007; 46:936.
  • 20
    Guis S, Balandraud N, Bouvenot J et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007; 57:142630.
  • 21
    Mugnier B, Roudier J. Factors predicting responsiveness to anti-TNFalpha therapy in patients with rheumatoid arthritis: using biotherapies rationally. Joint Bone Spine 2004; 71:914.
  • 22
    Maini R, St Breedveld EW, Clair F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354:19329.
  • 23
    Wolbink GJ, Voskuyl A, Lems WF et al. Relationship between serum trough infliximab levels, pretreatment C reactive, protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64:7047.
  • 24
    Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxf) 2006; 45:155865.
  • 25
    Weaver AL, Lautzenheiser RL, Schiff MH et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 2006; 22:18598.
  • 26
    Lequerre T, Vittecoq O, Le Loet X. Comments about the editorial by Benedicte Mugnier and Jean Roudier entitled ‘Factors predicting responsiveness to anti-TNFalpha therapy in patients with rheumatoid arthritis: using biotherapies rationally’. Joint Bone Spine 2005; 72:3467; author reply 7–8.
  • 27
    Buch MH, Seto Y, Bingham SJ et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 2005; 52:428.
  • 28
    Wolbink GJ, Groot E DE, Lems WF, Nurmohamed MT, Tak T, Dijmans BAC. Relationship between serum levels of infliximab, C-reactive protein and clinical response to infliximab patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62(SI ): 98 [Abstract.
  • 29
    Drynda S, Ringel B, Kekow M et al. Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFalpha therapy. Pathol Res Pract 2004; 200:16571.
  • 30
    Jarvis JN, Centola M. Gene-expression profiling: time for clinical application? Lancet 2005; 365:199200.
  • 31
    Bargnoux AS, Bonardet A, Chong G et al. Evaluation of an immunoassay (Abbott-IMX Analyzer) allowing routine determination of sirolimus: comparison with LC-MS method. Transplant Proc 2006; 38:23523.
  • 32
    Dupuy AM, Lehmann S, Cristol JP. Protein biochip systems for the clinical laboratory. Clin Chem Lab Med 2005; 43:1291302.
  • 33
    Lequerre T, Gauthier-Jauneau AC, Bansard C et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 2006; 8:R105.
  • 34
    Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 2006; 65 (Suppl 3):iii215.
  • 35
    Fitzgerald SP, Lamont JV, McConnell RI, Benchikh el O. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 2005; 51:116576.
  • 36
    Serio F DI, Amodio G, Ruggieri E et al. Proteomic approach to the diagnosis of acute coronary syndrome: preliminary results. Clin Chim Acta 2005; 357:22635.
  • 37
    Badiou S, Cristol JP, Jaussent I et al. Fine-tuning of the prediction of mortality in hemodialysis patients by use of cytokine proteomic determination. Clin J Am Soc Nephrol. 2008; 3:42330.
  • 38
    Brieland JK, Flory CM, Jones ML et al. Regulation of monocyte chemoattractant protein-1 gene expression and secretion in rat pulmonary alveolar macrophages by lipopolysaccharide, tumor necrosis factor-alpha, and interleukin-1 beta. Am J Respir Cell Mol Biol 1995; 12:1049.
  • 39
    DeForge LE, Kenney JS, Jones ML, Warren JS, Remick DG. Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. Separation of LPS- and cytokine-stimulated components using anti-tumor necrosis factor and anti-IL-1 antibodies. J Immunol 1992; 148:213341.
  • 40
    Koch AE, Kunkel SL, Harlow LA et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992; 90:7729.
  • 41
    Taberner M, Scott KF, Weininger L, Mackay CR, Rolph MS. Overlapping gene expression profiles in rheumatoid fibroblast-like synoviocytes induced by the proinflammatory cytokines interleukin-1 beta and tumor necrosis factor. Inflamm Res 2005; 54:1016.
  • 42
    Tian B, Nowak DE, Jamaluddin M, Wang S, Brasier AR. Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling. J Biol Chem 2005; 280:1743548.
  • 43
    Zhou A, Scoggin S, Gaynor RB, Williams NS. Identification of NF-kappa B-regulated genes induced by TNFalpha utilizing expression profiling and RNA interference. Oncogene 2003; 22:205464.
  • 44
    Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K, Kashiwazaki S. Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol 1993; 69:8391.
  • 45
    Taylor PC, Peters AM, Paleolog E et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43:3847.
  • 46
    Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19:16396.
  • 47
    Haynes PP Youssef, DR, Triantafillou S et al. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum 1997; 40:14008.
  • 48
    Satoh K, Kikuchi S, Sekimata M, Kabuyama Y, Homma MK, Homma Y. Involvement of ErbB-2 in rheumatoid synovial cell growth. Arthritis Rheum 2001; 44:2605.
  • 49
    Klooster AR, Bernier SM. Tumor necrosis factor alpha and epidermal growth factor act additively to inhibit matrix gene expression by chondrocyte. Arthritis Res Ther 2005; 7:R127–38.
  • 50
    Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24:52933.
  • 51
    Hrycaj P, Korczowska I, Lacki JK. Infliximab in rheumatoid arthritis: can the response be predicted? Ann Rheum Dis 2003; 62(SI ):403 [Abstract.
  • 52
    Moller B, Villiger PM. Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol 2006.